Detection, prognosis and treatment

Clinical advances for breast cancer will utilize novel imaging technologies, new biomarkers, and genomic/proteomic approaches for more accurate diagnosis and prognosis. We encourage projects whose aims are on the critical path for translation. We support research into less toxic and more individualized therapies, mechanisms of drug resistance, and studies to evaluate alternative medicines and natural products. We encourage research that recognizes the critical role that the delivery of clinical solutions has on health equity.

Specific topics include:

Imaging, biomarkers, and molecular pathology: Improving detection and diagnosis — We encourage research into new, cost-effective technological and biological approaches for molecular imaging and new approaches for tumor analysis at the individual patient level. This includes advanced types of molecular classification, new biomarker development, and improved technologies for patient diagnosis and prognosis, especially using techniques to replace the current practice of screening mammography and biopsy. We encourage studies that consider the extent to which the proposed new approaches can be accessible and beneficial to communities with limited access to health care

Innovative treatment modalities: Search for a cure — Promising leads from biology-based studies are encouraged to begin the critical path to clinical translation. Examples include immunotherapy, delivery technologies, gene therapy, new drug development/testing, and new approaches to clinical decision-making. Testing investigational anti-breast cancer agents for mechanism of action and identifying patient populations for which they are most effective are encouraged. We encourage an emphasis on patient populations bearing a disproportionate burden of the disease and/or lack of access to research and clinical treatment advances.